Neonatal Neutrophil Normal and Abnormal Physiology

Parravicini, Elvira; Ven, Carmella van de; Cairo, Mitchell S.

doi:10.1016/b978-0-7216-9654-6.50160-0

Cited by 1 publication

(2 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Developmental quantitative and qualitative neutrophil defects contribute to the increased susceptibility of neonates to infection (3). Dysregulation of the expression and production of haematopoetic cytokines contributes to the neutrophil defect (1,2). Neutrophils constitute the most important part of the phagocytic pool.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Randomized, Double-blinded, Placebo-controlled Trial of Early Administration of Recombinant Human Granulocyte Colony-stimulating Factor to Non-neutropenic Preterm Newborns Between 33 and 36 Weeks with Presumed Sepsis

Küçüködük¹,

Sezer²,

Yıldıran³

et al. 2002

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

A randomized, double-blinded, placebo-controlled trial was conducted of early administration of recombinant granulocyte colony-stimulating factor (rGCSF) to 40 non-neutropenic, preterm infants between 33 and 36 weeks of gestational age with the diagnosis of presumed sepsis. The treatment group (n = 20) received 5 microg/kg per day of intravenous rGCSF once daily for 3 d and the control group (n = 20) received the same volume of physiological serum. Immediately before the first dose and on the 4th day, plasma levels of GCSF and tumour necrosis factor-alpha (TNF-alpha), absolute neutrophil counts (ANC), immature neutrophil count (INC), immature/total neutrophil (I/T) ratios and platelet counts were determined. At study entry, the plasma GCSF and TNF-alpha levels were similar. On day 4, there was no significant change in GCSF levels in either groups, whereas there was a significant decrease in TNF-alpha levels in the treatment group. ANC and INC of the treatment group also increased significantly. The I/T ratio continued at the same level in the treatment group, but decreased significantly on days 4 and 7 day in the control group. The length of time on the neonatal intensive care unit (NICU) was significantly shorter in the treatment group. In conclusion, early administration of 3 daily doses of rGCSF (5 microg/kg per day) to non-neutropenic, preterm infants who had presumed sepsis increased circulating ANC and INC, decreased plasma TNF-alpha levels and shortened the length of time on the NICU.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Sepsis continues to be an important cause of morbidity and mortality among both full-term and preterm infants secondary to an immaturity in neonatal host defence (1,2). Developmental quantitative and qualitative neutrophil defects contribute to the increased susceptibility of neonates to infection (3).…”

Section: Introductionmentioning

confidence: 99%